Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Emberton M, Cornel EB, Bassi PF et al (2008) Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract 62:1076–1086
2. McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803
3. O’Leary MP (2000) LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology 56:7–11
4. Gravas S, Cornu JN, Drake MJ et al (2018) EAU guidelines on the management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Available at:
http://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/
. Accessed 5 May 2019
5. Debruyne F, Barkin J, van Erps P et al (2004) Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 46:488–494 (discussion 95)
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献